Status:
RECRUITING
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
Lead Sponsor:
Sun Yat-sen University
Conditions:
Laryngeal Cancer
Hypopharynx Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Car...
Eligibility Criteria
Inclusion
- Laryngeal (T3-4N0-3M0 ) and hypopharyngeal ( T2-4N0-3M0) cancers staged by AJCC8th
- age 18-70
- PS score 0-1
- normal functions to tolerate chemotherapy, immunotherapy and radiotherapy
Exclusion
- Patients with a combination of other malignant tumours
- Individuals with contraindications to immunotherapy
Key Trial Info
Start Date :
September 11 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 11 2027
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06611137
Start Date
September 11 2024
End Date
September 11 2027
Last Update
September 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060